Conatus Pharmaceuticals Inc (NDAQ:CNAT) had its price target increased by research analysts at Stifel Nicolaus from $7.00 to $9.00 in a report released on Thursday. The brokerage currently has a “buy” rating on the stock.

Shares of Conatus Pharmaceuticals (NDAQ:CNAT) opened at 4.69 on Thursday. The firm has a 50-day moving average price of $4.77 and a 200-day moving average price of $3.16. The stock’s market cap is $118.06 million. Conatus Pharmaceuticals has a one year low of $1.45 and a one year high of $6.30.

Your IP Address:

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.